Erratum To: Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events

Advances in Therapy - United States
doi 10.1007/s12325-014-0118-8
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Idiopathic Pulmonary Fibrosis and Pirfenidone

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2010English

Role of Pirfenidone in the Management of Pulmonary Fibrosis

Therapeutics and Clinical Risk Management
2017English

Pirfenidone Treatment in Idiopathic Pulmonary Fibrosis: Nationwide Danish Results

European Clinical Respiratory Journal
2016English

Efficacy of Pirfenidone in Patients With Advanced-Stage Idiopathic Pulmonary Fibrosis

Internal Medicine
Internal MedicineMedicine
2013English

Advances in the Management of Idiopathic Pulmonary Fibrosis

F1000 Medicine Reports
2010English

Effect of Perioperative Pirfenidone Treatment in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis

Annals of Thoracic Surgery
Respiratory MedicinePulmonaryCardiovascular MedicineSurgeryCardiology
2016English

Cardiovascular Risks, Bleeding Risks, and Clinical Events From 3 Phase III Trials of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

Advances in Therapy
MedicinePharmacology
2019English

Pirfenidone Should Be Prescribed for Patients With Idiopathic Pulmonary Fibrosis: Table 1

Thorax
PulmonaryRespiratory Medicine
2013English

Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis and More Advanced Lung Function Impairment

Respiratory Medicine
PulmonaryRespiratory Medicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy